文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

早发型特应性皮炎患者发生儿童葡萄膜炎的风险

Risk of Developing Pediatric Uveitis Among Patients With Early-Onset Atopic Dermatitis.
PubMed 文献 · JAMA Ophthalmol · 2025-01-01

这项基于美国 TriNetX 协作研究网络电子健康记录的队列研究,纳入 2004 年 1 月 1 日至 2024 年 12 月 14 日期间早发型特应性皮炎(AD)患儿及倾向评分匹配的无 AD 对照,比较儿童葡萄膜炎发生风险;AD 队列葡萄膜炎风险高于对照(HR 1.92,95%CI 1.38-2.66),重度 AD 较非重度 AD 风险更高(HR 3.64,95%CI 2.00-6.66),作者认为早发型 AD 儿童可能需要考虑眼科监测。

要点

  • 早发型 AD 患儿发生儿童葡萄膜炎的风险高于匹配对照(HR 1.92,95%CI 1.38-2.66)。
  • 排除 dupilumab 使用或自身免疫病后风险仍升高(HR 分别为 1.77、1.52)。
  • 重度 AD 较非重度 AD 的儿童葡萄膜炎风险更高(HR 3.64,95%CI 2.00-6.66)。

核心结论

  • 早发型 AD 儿童发生儿童葡萄膜炎的风险较匹配对照升高,且不依赖于自身免疫病或 dupilumab 使用。
  • 作者认为这些发现支持早发型 AD 儿童可能需要考虑眼科监测,以便发现并随后管理发生的葡萄膜炎。

研究设计与样本

  • 这项队列研究使用美国 TriNetX 协作研究网络电子健康记录,纳入 2004 年 1 月 1 日至 2024 年 12 月 14 日的早发型 AD 患者及匹配对照,并采用倾向评分匹配平衡基线特征。
  • 分析于 2024 年 12 月 14 日进行,暴露为国际疾病分类第 10 版(ICD-10)AD 诊断代码,排除 AD 诊断前已有葡萄膜炎者。
  • 匹配后 AD 队列 114 889 例(平均[SD]随访 6.0[3.3]年;平均[SD]年龄 0.5[0.7]岁;男性 64 817 例[56.4%]),对照队列平均[SD]随访 6.6[3.7]年、平均[SD]年龄 0.6[0.8]岁、男性 65 377 例[56.9%]。

主要发现

  • AD 队列儿童葡萄膜炎发生率高于对照(94 例[0.08%] vs 58 例[0.05%];HR 1.92[95%CI 1.38-2.66])。
  • 在未使用 dupilumab 的患者中,AD 队列 113 284 例中 89 例[0.08%] vs 对照 113 284 例中 59 例[0.05%](HR 1.77[95%CI 1.27-2.46])。
  • 在无自身免疫病的患者中,AD 队列 114 425 例中 80 例[0.07%] vs 对照 114 425 例中 61 例[0.05%](HR 1.52[95%CI 1.09-2.12])。
  • 重度 AD 较非重度 AD 的儿童葡萄膜炎风险更高(12/3004[0.40%] vs 97/126 482[0.08%];HR 3.64[95%CI 2.00-6.66])。

关键数值与推荐

  • 主要结局为 AD 队列较匹配对照发生儿童葡萄膜炎的风险比(HR),采用 Cox 比例风险模型评估。
  • AD 队列 vs 对照:HR 1.92(95%CI 1.38-2.66)。
  • 未使用 dupilumab 者:HR 1.77(95%CI 1.27-2.46);无自身免疫病者:HR 1.52(95%CI 1.09-2.12)。
  • 重度 AD vs 非重度 AD:HR 3.64(95%CI 2.00-6.66)。

临床怎么用

  • 作者认为这些发现支持早发型 AD 儿童可能需要考虑眼科监测,以便发现并随后管理发生的葡萄膜炎。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The relationship between atopic dermatitis (AD) and pediatric uveitis may be underexplored, warranting large-scale, multicenter studies. OBJECTIVE: To evaluate the risk of pediatric uveitis among children with early-onset AD compared with a matched control population. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used aggregated electronic health records of US patients with early-onset AD and matched controls from January 1, 2004, through December 14, 2024, sourced from health care organizations in the collaborative research network TriNetX. Patients with early-onset AD and matched controls without AD were included in the analysis; those with uveitis prior to AD diagnosis were excluded. Propensity score matching was applied to balance baseline characteristics. The analyses were conducted on December 14, 2024. EXPOSURE: International Classification of Diseases, 10th Revision (ICD-10) diagnosis code for AD. MAIN OUTCOMES AND MEASURES: The primary outcome was the hazard ratio (HR) for developing pediatric uveitis in the AD cohort compared with the matched controls. Cox proportional hazards models were applied to assess the risk. RESULTS: A total of 114 889 patients were identified in the AD cohort (mean [SD] follow-up, 6.0 [3.3] years; mean [SD] age, 0.5 [0.7] years; 64 817 male [56.4%]) and the control cohort (mean [SD] follow-up, 6.6 [3.7] years; mean [SD] age, 0.6 [0.8] years; 65 377 male [56.9%]) after matching. The AD cohort demonstrated a higher risk of developing pediatric uveitis compared with controls (94 [0.08%] vs 58 [0.05%]; HR, 1.92 [95% CI, 1.38-2.66]). Sensitivity analyses among patients without dupilumab use (89 of 113 284 [0.08%] vs 59 of 113 284 [0.05%]; HR, 1.77 [95% CI, 1.27-2.46]) and those without autoimmune conditions (80 of 114 425 [0.07%] vs 61 of 114 425 [0.05%]; HR, 1.52 [95% CI, 1.09-2.12]) similarly indicated an increased risk in the AD cohort. Additionally, patients with severe AD had a higher risk of developing pediatric uveitis compared with those with nonsevere AD (12 of 3004 [0.40%] vs 97 of 126 482 [0.08%]; HR, 3.64 [95% CI, 2.00-6.66]). CONCLUSIONS AND RELEVANCE: This cohort study of children with early-onset AD found an elevated risk of pediatric uveitis compared with matched controls, independent of autoimmune conditions or dupilumab use. These findings support the potential need to consider ophthalmologic monitoring in children with early-onset AD to try to detect and subsequently manage uveitis if it develops.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Chu YY, Sung CH, Lin YS, et al. Risk of Developing Pediatric Uveitis Among Patients With Early-Onset Atopic Dermatitis. JAMA Ophthalmol. 2025. PMID: 40178834. doi:10.1001/jamaophthalmol.2025.0366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。